Anumana vs PERISCOPE

A US hospital that requires an FDA decision before buying can consider only Anumana, whose newest ECG-AI clearance, for cardiac amyloidosis, was decided in April 2026. The vendor says its low ejection fraction algorithm is available for clinical use in the US and EU, and a cardiology department is the one that adopts it.

PERISCOPE is sold to hospital surgical departments, and Deventer Ziekenhuis and Amsterdam UMC supply its testimonials. The vendor says it is CE-marked as a Class IIa device under EU MDR and states no FDA status. It predicts post-operative bacterial infection risk 7 and 30 days after surgery from existing EHR data, with models fitted per hospital. A study in Lancet Regional Health Europe in 2025 was retrospective: 253,010 procedures at three hospitals in the Netherlands and Belgium, 30-day AUROC of 0.82, 0.82 and 0.91, with two authors at Healthplus.ai. The vendor says implementation takes 8 to 12 weeks depending on the EHR.